Some studies, such as the ORIGIN trial, suggest a potential increased risk of cardiovascular events, particularly in patients receiving high doses of insulin or those with advanced disease, likely due to insulin's association with weight gain, hypoglycemia, and potentially adverse metabolic effects, including hyperinsulinemia and endothelial dysfunction [28]. This evidence concerns the gene INS and hyperinsulinism.